source
- RA Capital backs four biotech rounds in September as Novartis shares tumble after trial setbacksRA Capital Management participated in four biotech financings in September, including Series A rounds for Solstice Oncology and Tectora Therapeutics, as well as co-leading a $56 million round for T…
- mRNA cancer vaccines’ biggest barriers to marketManufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.